Logo image of MGTA

MAGENTA THERAPEUTICS INC (MGTA) Stock Fundamental Analysis

NASDAQ:MGTA - Nasdaq - US55910K1088 - Common Stock - Currency: USD

0.6996  -0.06 (-7.74%)

Fundamental Rating

3

MGTA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MGTA as it has an excellent financial health rating, but there are worries on the profitability. MGTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MGTA has reported negative net income.
MGTA had a negative operating cash flow in the past year.
MGTA had negative earnings in each of the past 5 years.
In the past 5 years MGTA always reported negative operating cash flow.
MGTA Yearly Net Income VS EBIT VS OCF VS FCFMGTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

MGTA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGTA Yearly ROA, ROE, ROICMGTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

MGTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGTA Yearly Profit, Operating, Gross MarginsMGTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, MGTA has more shares outstanding
There is no outstanding debt for MGTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MGTA Yearly Shares OutstandingMGTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
MGTA Yearly Total Debt VS Total AssetsMGTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -8.66, we must say that MGTA is in the distress zone and has some risk of bankruptcy.
MGTA has a Altman-Z score of -8.66. This is in the lower half of the industry: MGTA underperforms 77.59% of its industry peers.
There is no outstanding debt for MGTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.66
ROIC/WACCN/A
WACCN/A
MGTA Yearly LT Debt VS Equity VS FCFMGTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 19.49 indicates that MGTA has no problem at all paying its short term obligations.
MGTA has a better Current ratio (19.49) than 93.08% of its industry peers.
A Quick Ratio of 19.49 indicates that MGTA has no problem at all paying its short term obligations.
MGTA's Quick ratio of 19.49 is amongst the best of the industry. MGTA outperforms 93.08% of its industry peers.
Industry RankSector Rank
Current Ratio 19.49
Quick Ratio 19.49
MGTA Yearly Current Assets VS Current LiabilitesMGTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

MGTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.98%, which is quite good.
EPS 1Y (TTM)12.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.46% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.37%
EPS Next 2Y41.98%
EPS Next 3Y26.32%
EPS Next 5Y6.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGTA Yearly Revenue VS EstimatesMGTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 50M 100M 150M 200M
MGTA Yearly EPS VS EstimatesMGTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGTA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 34.29, which means the current valuation is very expensive for MGTA.
MGTA's Price/Forward Earnings ratio is rather cheap when compared to the industry. MGTA is cheaper than 94.73% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.44. MGTA is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 34.29
MGTA Price Earnings VS Forward Price EarningsMGTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGTA Per share dataMGTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MGTA's earnings are expected to grow with 26.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.98%
EPS Next 3Y26.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAGENTA THERAPEUTICS INC

NASDAQ:MGTA (9/11/2023, 8:06:21 PM)

0.6996

-0.06 (-7.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)11-01 2023-11-01
Inst Owners190.47%
Inst Owner Change-75.34%
Ins Owners339.14%
Ins Owner Change0%
Market Cap2.65M
Analysts43.33
Price Target1.02 (45.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.71%
Min EPS beat(2)-14.78%
Max EPS beat(2)74.2%
EPS beat(4)2
Avg EPS beat(4)11.93%
Min EPS beat(4)-23.46%
Max EPS beat(4)74.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-74.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 34.29
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)0.02
Fwd EY2.92%
FCF(TTM)-19.27
FCFYN/A
OCF(TTM)-19.16
OCFYN/A
SpS0
BVpS19.68
TBVpS19.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.49
Quick Ratio 19.49
Altman-Z -8.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)33.04%
Cap/Depr(5y)227.4%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.76%
EPS Next Y34.37%
EPS Next 2Y41.98%
EPS Next 3Y26.32%
EPS Next 5Y6.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.38%
OCF growth 3YN/A
OCF growth 5YN/A